» Articles » PMID: 36233635

Genetic Testing for a Patient with Suspected 3 Beta-Hydroxysteroid Dehydrogenase Deficiency: A Case of Unreported Genetic Variants

Overview
Journal J Clin Med
Specialty General Medicine
Date 2022 Oct 14
PMID 36233635
Authors
Affiliations
Soon will be listed here.
Abstract

3beta-hydroxysteroid dehydrogenase type II deficiency (HSD3B2 deficiency), a rare form of congenital adrenal hyperplasia (CAH), is characterized by varying degrees of salt loss and incomplete masculinization in males and mild virilization or normal external genitalia in females. We report the case of a patient (46XY) showing salt loss and incomplete masculinization, markedly elevated levels of 17OHP (17 hydroxyprogesterone), ACTH (Adreno Cortico Tropic Hormone), testosterone and delta4androstenedione (delta4A), low levels of cortisol and absence of bone skeletal alterations that frequently characterize POR (Cytochrome P450 oxidoreductase) deficiency. Mutation analysis by Sanger sequencing of the HSD3B2 gene showed that the patient presented with a compound heterozygote for two novel variants c.370A>G p.Ser124Gly and c.308-6 G>A. The two HSD3B2 gene variants were also present in the patient’s older brother showing only incomplete masculinization. The in silico analysis revealed a probable damaging effect of c.370A>G p.Ser124Gly: residue p.Ser124 is highly conserved among species and seems to be located in the catalytic site of the enzyme, playing a pivotal role in NAD(H) binding to its substrate. Intronic c.308-6G>A variant is predicted to be likely pathogenic; the substitution seems to cause a change in the splice acceptor site located 6bp downstream of the variant. The two siblings seem to be affected by 3β-HSD2 deficiency; nevertheless, the two novel variants are likely to cause variable expressivity of the disease.

Citing Articles

Evaluation of 3β-hydroxysteroid dehydrogenase activity using progesterone and androgen receptors-mediated transactivation.

Yazawa T, Watanabe Y, Yokohama Y, Imamichi Y, Hasegawa K, Nakajima K Front Endocrinol (Lausanne). 2024; 15:1480722.

PMID: 39415787 PMC: 11479897. DOI: 10.3389/fendo.2024.1480722.

References
1.
Rainey W, Nakamura Y . Regulation of the adrenal androgen biosynthesis. J Steroid Biochem Mol Biol. 2007; 108(3-5):281-6. PMC: 2699571. DOI: 10.1016/j.jsbmb.2007.09.015. View

2.
Rheaume E, Simard J, Morel Y, Mebarki F, ZACHMANN M, Forest M . Congenital adrenal hyperplasia due to point mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene. Nat Genet. 1992; 1(4):239-45. DOI: 10.1038/ng0792-239. View

3.
Lorence M, Murry B, Trant J, Mason J . Human 3 beta-hydroxysteroid dehydrogenase/delta 5----4isomerase from placenta: expression in nonsteroidogenic cells of a protein that catalyzes the dehydrogenation/isomerization of C21 and C19 steroids. Endocrinology. 1990; 126(5):2493-8. DOI: 10.1210/endo-126-5-2493. View

4.
Lachance Y, Luu-The V, Verreault H, Dumont M, Rheaume E, Leblanc G . Structure of the human type II 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) gene: adrenal and gonadal specificity. DNA Cell Biol. 1991; 10(10):701-11. DOI: 10.1089/dna.1991.10.701. View

5.
Guran T, Kara C, Yildiz M, Bitkin E, Haklar G, Lin J . Revisiting Classical 3β-hydroxysteroid Dehydrogenase 2 Deficiency: Lessons from 31 Pediatric Cases. J Clin Endocrinol Metab. 2020; 105(3). DOI: 10.1210/clinem/dgaa022. View